YDYasmin Dahabreh

Yasmin Dahabreh

*This is an algorithmically generated author record based on publicly available information.

Yasmin Dahabreh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unmasking Hirata: a mysterious case of Hypoglycemia triggered by immunologic storm

    by Mohammed AbuBaha, Hossam Salameh, Bara AbuBaha, Yasmin Dahabreh, Omar Marouf, Mousa Atary, Heba Qubaja, Amal Mansor, Hatem M Taha

    We report a rare case of Insulin Autoimmune Syndrome in a 35-year-old woman with prior autoimmune features who developed hypoglycemia after an allergic reaction. Diagnosis was confirmed by insulin autoantibodies. Immunosuppressive therapy yielded significant improvement. This case suggests a broader autoimmune process may underlie seemingly isolated IAS presentations.


  • Open Access

    Laser-Induced Thermal Therapy in the Management of Low-Grade Gliomas: A Narrative Review

    by Ibrahim Omar Hamed Dalabeh, Hossam Salameh, Yasmin Dahabreh, Abdallah Ali Suleiman Al-Zayadneh, Mehreen Amir, Ayman Haitham Khaled, Malak A. Hassan, Azad Jehad Makableh, Mohammad Omar Hamed Dalabeh

    Background: Low-grade gliomas (LGGs) are slow-growing, World Health Organization Grade I and II tumors that can transform into more aggres-sive malignancies over time. This transformation pre- sents significant challenges in managing the burden of health care. Laser-induced thermal therapy (LITT) has emerged as a promising minimally invasive treat-ment option for LGGs, offering precise tumor ablation with minimal damage to surrounding tissues. Method: This narrative review synthesizes data from relevant studies on the evolution, clinical manifestations, mo-lecular characteristics, and emerging management strategies for LGGs, with a focus on the role of LITT. Results: LITT, a minimally invasive technique, offers targeted tumor ablation with the added benefit of disrupting the blood-brain barrier to enhance drug delivery. Studies have shown that LITT can effectively reduce tumor size and improve survival rates in patients with both primary and recurrent gliomas. However, challenges such as procedure-related complications, including motor deficits and cerebral edema, as well as the need for further research on long-term efficacy, remain. Conclusion: LITT represents a significant advancement in the treatment of LGGs, combining precision and minimal invasiveness. Future studies should focus on optimiz-ing protocols, integrating molecular and genetic in-sights, and assessing long-term outcomes to enhance therapeutic efficacy and patient quality of life.